Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors

NCT07259304 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2025-12-02

No results posted yet for this study

Summary

This study assesses how personal relationships (such as friendships, family relationships, or romantic partners) influence the physical activity (exercise) and well-being of young adult cancer survivors. Researchers also hope to learn how social relationships change after a cancer diagnosis, and how these changes might impact important health behaviors. The information provided may help researchers learn more about better ways to support young cancer patients in the future through interventions that help maintain good social relationships and health levels of physical activity.

Conditions

  • Anatomic Stage I Breast Cancer AJCC v8
  • Anatomic Stage IA Breast Cancer AJCC v8
  • Anatomic Stage IB Breast Cancer AJCC v8
  • Anatomic Stage II Breast Cancer AJCC v8
  • Anatomic Stage IIA Breast Cancer AJCC v8
  • Anatomic Stage IIB Breast Cancer AJCC v8
  • Anatomic Stage III Breast Cancer AJCC v8
  • Anatomic Stage IIIA Breast Cancer AJCC v8
  • Anatomic Stage IIIB Breast Cancer AJCC v8
  • Anatomic Stage IIIC Breast Cancer AJCC v8
  • Central Nervous System Neoplasm
  • Clinical Stage I Cutaneous Melanoma AJCC v8
  • Clinical Stage IA Cutaneous Melanoma AJCC v8
  • Clinical Stage IB Cutaneous Melanoma AJCC v8
  • Clinical Stage II Cutaneous Melanoma AJCC v8
  • Clinical Stage IIA Cutaneous Melanoma AJCC v8
  • Clinical Stage IIB Cutaneous Melanoma AJCC v8
  • Clinical Stage IIC Cutaneous Melanoma AJCC v8
  • Clinical Stage III Cutaneous Melanoma AJCC v8
  • Hodgkin Lymphoma
  • Malignant Bone Neoplasm
  • Malignant Brain Neoplasm
  • Malignant Solid Neoplasm
  • Malignant Testicular Neoplasm
  • Non-Hodgkin Lymphoma
  • Pathologic Stage I Cutaneous Melanoma AJCC v8
  • Pathologic Stage IA Cutaneous Melanoma AJCC v8
  • Pathologic Stage IB Cutaneous Melanoma AJCC v8
  • Pathologic Stage II Cutaneous Melanoma AJCC v8
  • Pathologic Stage IIA Cutaneous Melanoma AJCC v8
  • Pathologic Stage IIB Cutaneous Melanoma AJCC v8
  • Pathologic Stage IIC Cutaneous Melanoma AJCC v8
  • Pathologic Stage III Cutaneous Melanoma AJCC v8
  • Pathologic Stage IIIA Cutaneous Melanoma AJCC v8
  • Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
  • Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
  • Pathologic Stage IIID Cutaneous Melanoma AJCC v8
  • Prognostic Stage I Breast Cancer AJCC v8
  • Prognostic Stage IA Breast Cancer AJCC v8
  • Prognostic Stage IB Breast Cancer AJCC v8
  • Prognostic Stage II Breast Cancer AJCC v8
  • Prognostic Stage IIA Breast Cancer AJCC v8
  • Prognostic Stage IIB Breast Cancer AJCC v8
  • Prognostic Stage III Breast Cancer AJCC v8
  • Prognostic Stage IIIA Breast Cancer AJCC v8
  • Prognostic Stage IIIB Breast Cancer AJCC v8
  • Prognostic Stage IIIC Breast Cancer AJCC v8
  • Stage I Cervical Cancer AJCC v8
  • Stage I Colorectal Cancer AJCC v8
  • Stage I Differentiated Thyroid Gland Carcinoma AJCC v8
  • Stage I Ovarian Cancer AJCC v8
  • Stage I Thyroid Gland Medullary Carcinoma AJCC v8
  • Stage I Uterine Corpus Cancer AJCC v8
  • Stage IA Cervical Cancer AJCC v8
  • Stage IA Ovarian Cancer AJCC v8
  • Stage IA Uterine Corpus Cancer AJCC v8
  • Stage IA1 Cervical Cancer AJCC v8
  • Stage IA2 Cervical Cancer AJCC v8
  • Stage IB Cervical Cancer AJCC v8
  • Stage IB Ovarian Cancer AJCC v8
  • Stage IB Uterine Corpus Cancer AJCC v8
  • Stage IB1 Cervical Cancer AJCC v8
  • Stage IB2 Cervical Cancer AJCC v8
  • Stage IC Ovarian Cancer AJCC v8
  • Stage II Cervical Cancer AJCC v8
  • Stage II Colorectal Cancer AJCC v8
  • Stage II Differentiated Thyroid Gland Carcinoma AJCC v8
  • Stage II Ovarian Cancer AJCC v8
  • Stage II Thyroid Gland Medullary Carcinoma AJCC v8
  • Stage II Uterine Corpus Cancer AJCC v8
  • Stage IIA Cervical Cancer AJCC v8
  • Stage IIA Colorectal Cancer AJCC v8
  • Stage IIA Ovarian Cancer AJCC v8
  • Stage IIA1 Cervical Cancer AJCC v8
  • Stage IIA2 Cervical Cancer AJCC v8
  • Stage IIB Cervical Cancer AJCC v8
  • Stage IIB Colorectal Cancer AJCC v8
  • Stage IIB Ovarian Cancer AJCC v8
  • Stage IIC Colorectal Cancer AJCC v8
  • Stage III Cervical Cancer AJCC v8
  • Stage III Colorectal Cancer AJCC v8
  • Stage III Differentiated Thyroid Gland Carcinoma AJCC v8
  • Stage III Ovarian Cancer AJCC v8
  • Stage III Thyroid Gland Medullary Carcinoma AJCC v8
  • Stage III Uterine Corpus Cancer AJCC v8
  • Stage IIIA Cervical Cancer AJCC v8
  • Stage IIIA Colorectal Cancer AJCC v8
  • Stage IIIA Ovarian Cancer AJCC v8
  • Stage IIIA Uterine Corpus Cancer AJCC v8
  • Stage IIIA1 Ovarian Cancer AJCC v8
  • Stage IIIA2 Ovarian Cancer AJCC v8
  • Stage IIIB Cervical Cancer AJCC v8
  • Stage IIIB Colorectal Cancer AJCC v8
  • Stage IIIB Ovarian Cancer AJCC v8
  • Stage IIIB Uterine Corpus Cancer AJCC v8
  • Stage IIIC Colorectal Cancer AJCC v8
  • Stage IIIC Ovarian Cancer AJCC v8
  • Stage IIIC Uterine Corpus Cancer AJCC v8
  • Stage IIIC1 Uterine Corpus Cancer AJCC v8
  • Stage IIIC2 Uterine Corpus Cancer AJCC v8

Interventions

OTHER

Survey Administration

Complete survey

OTHER

Quality-of-Life Assessment

Complete survey

OTHER

Medical Device Usage and Evaluation

Wear an actigraph GT3X-BT accelerometer

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH
  • University of Southern California

    lead OTHER

Principal Investigators

  • Kimberly Miller, PhD · University of Southern California

Eligibility

Min Age
18 Years
Max Age
39 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-24
Primary Completion
2026-12-31
Completion
2027-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07259304 on ClinicalTrials.gov